Literature DB >> 20503148

Serum concentrations of citalopram--dose-dependent variation in R- and S-enantiomer ratios.

L Tanum1, L P Strand, H Refsum.   

Abstract

INTRODUCTION: The antidepressive effect of racemic citalopram (CIT) is exerted by S-CIT, while R-CIT is a partial antagonist to S-CIT. Since R-and S-CIT are metabolized by different pathways, we investigated whether the ratio of S- and R-CIT may differ between individuals on the same dose of racemic CIT, and if a possible variability in the R/S-ratio could be dose-dependent.
METHODS: A chiral analysis of R- and S-CIT in serum samples taken from 88 female patients receiving treatment with racemic CIT was performed using high-pressure liquid chromatography.
RESULTS: The mean levels of R-CIT were significantly higher than those of S-CIT in all dose groups. The R/S-CIT ratio increased from 1.99 to 2.45 with an increase in the dose (p<0.05), and the interindividual variance in the R/S-CIT ratio was up to four-fold on the same dosage. DISCUSSION: Our findings show that the stereoselective metabolism of citalopram IN VIVO has pharmacokinetic consequences reflected by dose dependent variations of enantiomeric drug concentrations, as well as substantial interindividual variabilities in the ratios of the concentrations. The clinical consequences, however, are unclear and should be further explored. Copyright Georg Thieme Verlag KG Stuttgart New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503148     DOI: 10.1055/s-0030-1254106

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  4 in total

1.  "There is no dose-response relationship in psychopharmacotherapy" vs "pharmacotherapy in psychiatry is based on ligand-receptor interaction": a unifying hypothesis and the need for plasma concentration based clinical trials.

Authors:  Vincent Eggart; Christoph Hiemke; Gerald Zernig
Journal:  Psychopharmacology (Berl)       Date:  2011-05-04       Impact factor: 4.530

2.  Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.

Authors:  Perrine Courlet; Monia Guidi; Anaïs Glatard; Susana Alves Saldanha; Matthias Cavassini; Thierry Buclin; Catia Marzolini; Chin B Eap; Laurent A Decosterd; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2019-07-07       Impact factor: 4.335

Review 3.  Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.

Authors:  Huailing Zhong; Nasser Haddjeri; Connie Sánchez
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

4.  A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.

Authors:  Ayman Akil; Robert R Bies; Bruce G Pollock; Dimitrios Avramopoulos; D P Devanand; Jacobo E Mintzer; Anton P Porsteinsson; Lon S Schneider; Daniel Weintraub; Jerome Yesavage; David M Shade; Constantine G Lyketsos
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-26       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.